| Literature DB >> 33427645 |
Paul Guilhamon1,2, Charles Chesnelong2, Michelle M Kushida2, Ana Nikolic3,4,5, Divya Singhal3,4,5, Graham MacLeod6, Seyed Ali Madani Tonekaboni1,7, Florence Mg Cavalli2, Christopher Arlidge1, Nishani Rajakulendran6, Naghmeh Rastegar2, Xiaoguang Hao3,8,9, Rozina Hassam3,8,9, Laura J Smith10, Heather Whetstone2, Fiona J Coutinho2, Bettina Nadorp1, Katrina I Ellestad3,4, H Artee Luchman3,8,9, Jennifer Ai-Wen Chan3,4,11, Molly S Shoichet10, Michael D Taylor2,12,13, Benjamin Haibe-Kains1,7,14,15,16, Samuel Weiss3,8,9,17, Stephane Angers6,18, Marco Gallo3,4,5,17, Peter B Dirks2,12,15, Mathieu Lupien1,7.
Abstract
Chromatin accessibility discriminates stem from mature cell populations, enabling the identification of primitive stem-like cells in primary tumors, such as glioblastoma (GBM) where self-renewing cells driving cancer progression and recurrence are prime targets for therapeutic intervention. We show, using single-cell chromatin accessibility, that primary human GBMs harbor a heterogeneous self-renewing population whose diversity is captured in patient-derived glioblastoma stem cells (GSCs). In-depth characterization of chromatin accessibility in GSCs identifies three GSC states: Reactive, Constructive, and Invasive, each governed by uniquely essential transcription factors and present within GBMs in varying proportions. Orthotopic xenografts reveal that GSC states associate with survival, and identify an invasive GSC signature predictive of low patient survival, in line with the higher invasive properties of Invasive state GSCs compared to Reactive and Constructive GSCs as shown by in vitro and in vivo assays. Our chromatin-driven characterization of GSC states improves prognostic precision and identifies dependencies to guide combination therapies.Entities:
Keywords: ATAC; Glioblastoma; cancer biology; cancer stem cell; chromatin; human; single cell ATAC; tumor initiating cells
Mesh:
Substances:
Year: 2021 PMID: 33427645 PMCID: PMC7847307 DOI: 10.7554/eLife.64090
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.140